Intracranial hemorrhage with direct oral anticoagulants in patients with  brain tumors

ConclusionsA total of 172 patients with brain tumors were evaluated (42 DOAC and 131 LMWH). In the primary brain tumor cohort (N=67), the cumulative incidence ofanyICH was 0% in patients receiving DOACs versus 36.8% (95% CI, 22.3 ‐51.3%) in those treated with LMWH with amajorICH incidence of 18.2% (95% CI, 8.4 ‐31.0). In the brain metastases cohort (N=105), DOACs did not increase the risk ofanyICH relative to enoxaparin with an incidence of 27.8% (95% CI, 5.5 ‐56.7%) compared with 52.9% (95% CI, 37.4‐66.2%). Similarly, DOAC did not increase the incidence ofmajorICH in brain metastases with a cumulative incidence 11.1% (95% CI 0.5 ‐40.6%) versus 17.8% (95% CI 10.2‐27.2%). We conclude that DOACs are not associated with an increased incidence of ICH relative to LMWH in patients with brain metastases or primary brain tumors.This article is protected by copyright. All rights reserved.

Source: Journal of Thrombosis and Haemostasis - November 19, 2018 Category: Hematology Authors: Brian J. Carney, Erik J. Uhlmann, Maneka Puligandla, Charlene Mantia, Griffin M. Weber, Donna S. Neuberg, Jeffrey I. Zwicker Tags: Original Article ‐ Clinical Haemostasis and Thrombosis Source Type: research